title: Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts.
abstract: Lactoferrin, an iron-binding glycoprotein present in milk and other exocrine secretions in mammals, is anabolic to bone at physiological concentrations. Lactoferrin stimulates the proliferation, differentiation and survival of osteoblasts, as well as potently inhibiting osteoclastogenesis in bone marrow cultures. In the current study we further investigated the mechanism of action of lactoferrin in osteoblasts. We used low-density arrays to measure the level of expression of 45 genes in MC3T3-E1 osteoblast-like cells treated with lactoferrin, and identified transient, dose-dependent increases in the transcription levels of interleukin-6, of the pro-inflammatory factor prostaglandin-endoperoxide synthase 2 (Ptgs2), and of the transcription factor nuclear factor of activated T cells (Nfatc1). We demonstrated similar changes in primary osteoblast cultures from human and rat. Levels of prostaglandin E2 were increased in conditioned media collected from osteoblasts treated with lactoferrin, indicating that the activity of the enzyme cyclooxygenase 2 (COX2), which is encoded by Ptgs2, was also up-regulated. Using a luciferase reporter construct we showed that lactoferrin induced transcription from the NFAT consensus sequence. We found that inhibiting either COX2 or NFATc1 activity blocked the mitogenic effect of lactoferrin in osteoblasts and that inhibition of NFATc1 activity partially blocked the transcriptional activation of Ptgs2. Our study has provided the first evidence that COX2 and NFATc1 activities are increased by lactoferrin, and demonstrated a role for each of these molecules as mediators of the mitogenic effects of lactoferrin in osteoblasts.
authors.affiliation: Department of Medicine, University of Auckland, Auckland, New Zealand. d.naot@auckland.ac.nz
authors.forename: Dorit
authors.initials: D
authors.lastname: Naot
authors.forename: Ashika
authors.initials: A
authors.lastname: Chhana
authors.forename: Brya G
authors.initials: BG
authors.lastname: Matthews
authors.forename: Karen E
authors.initials: KE
authors.lastname: Callon
authors.forename: Pak C
authors.initials: PC
authors.lastname: Tong
authors.forename: Jian-Ming
authors.initials: JM
authors.lastname: Lin
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Costa
authors.forename: Maureen
authors.initials: M
authors.lastname: Watson
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Grey
authors.forename: Jillian
authors.initials: J
authors.lastname: Cornish
mesh_terms: D000818:Animals; D002460:Cell Line; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D015232:Dinoprostone / Q000235:genetics / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D007781:Lactoferrin / Q000494:pharmacology*; D051821:Lymphoid Enhancer-Binding Factor 1 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D050778:NFATC Transcription Factors / Q000235:genetics / Q000378:metabolism; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism*; D053244:Osteoprotegerin / Q000235:genetics / Q000378:metabolism; D016133:Polymerase Chain Reaction; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics / Q000378:metabolism; D051381:Rats; D051822:T Cell Transcription Factor 1 / Q000235:genetics / Q000378:metabolism; D000099169:Fos-Related Antigen 1
chemical_list: D051546:Cyclooxygenase 2; D015232:Dinoprostone; D015850:Interleukin-6; D007781:Lactoferrin; D051821:Lymphoid Enhancer-Binding Factor 1; D050778:NFATC Transcription Factors; D053244:Osteoprotegerin; D016760:Proto-Oncogene Proteins c-fos; D051822:T Cell Transcription Factor 1; D000099169:Fos-Related Antigen 1